Doctors’ ad-backed AI tool OpenEvidence draws mixed clinical evidence
Original title: The $15 billion ad-powered AI startup your doctor may already be using
A Mayo Clinic sample of five cases was favorable, while a Nature paper found it trailed Gemini and GPT on clinical benchmarks.
Ars Technica, citing the Financial Times, profiles OpenEvidence, an ad-supported AI product the headline values at $15 billion and that physicians are adopting on their own. Founder Nadler frames the goal as literature-based drug discovery, and Alexander Tarashansky, creator of Anthropic’s Claude Science, has joined. OpenAI offers ChatGPT for healthcare, and Anthropic partnered with OpenEvidence for tools in 100 low- and middle-income countries. A Mayo Clinic study, from an investor, found accurate advice in five sampled cases with limited effect on treatment decisions; a June Nature paper found it underperformed Gemini and GPT.
Unconfirmed: The $15 billion figure comes from the headline, and Nadler’s claims about physician trust are his own.
- Thrive Capital partner Nworah Ayogu cited voluntary physician adoption as a differentiator.
- NYU Langone neurosurgeon Eric Oermann said clinical implementation guidance is scarce.
- Concerns include junior doctors relying on the tool before learning core treatment knowledge.
- Mayo Clinic is both an investor and the source of the five-case study.
- Organizations
- AnthropicOpenAIMayo ClinicThrive CapitalNYU Langone
From the original article
2 min read at arstechnica.com
OpenEvidence is booming despite questions about accuracy and ads.
By Rafe Rosner-Uddin, Financial Times · arstechnica.com
A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.